2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Girgis S, Lin S, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang T, Hilder B, Jiao Q, Hanna B, Adams H, Sun Y, Sharma A, Smit J, Infante J, Goldberg J, Elsayed Y. Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Targeted Oncology 2022, 17: 433-439. PMID: 35749004, PMCID: PMC9345835, DOI: 10.1007/s11523-022-00893-y.Peer-Reviewed Original ResearchConceptsPhase I studyTherapeutic dose rangeSubcutaneous doseMultiple myelomaTherapeutic rangeActive dosesRecommended phase II doseDose rangeT cell-mediated cytotoxicityLow-dose cohortPhase II doseDose-escalation studyRelapsed/Refractory Multiple MyelomaWeekly subcutaneous dosesCD3 bispecific antibodyFirst-in-humanMultiple myeloma cellsII doseResultsThe doseEscalation studyIntravenous doseBone marrowPreclinical studiesB cellsClinical data
2018
An early history of T cell-mediated cytotoxicity
Golstein P, Griffiths G. An early history of T cell-mediated cytotoxicity. Nature Reviews Immunology 2018, 18: 527-535. PMID: 29662120, DOI: 10.1038/s41577-018-0009-3.Peer-Reviewed Original Research
2017
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment
Delitto D, Delitto AE, DiVita BB, Pham K, Han S, Hartlage ER, Newby BN, Gerber MH, Behrns KE, Moldawer LL, Thomas RM, George TJ, Brusko TM, Mathews CE, Liu C, Trevino JG, Hughes SJ, Wallet SM. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Cancer Research 2017, 77: 672-683. PMID: 27864347, PMCID: PMC5290036, DOI: 10.1158/0008-5472.can-16-1765.Peer-Reviewed Original ResearchConceptsTumor-associated stromaPancreatic cancerTumor microenvironmentT cell-mediated cytotoxicityCancer cell-conditioned mediumImmunosuppressive tumor microenvironmentT cell proliferationCell-conditioned mediumHuman cell culture modelsTh1 ratioProtective immunityCancer differsHealthy controlsMemory Th17Pancreatic lysatesCell culture modelPrimary human cell culture modelsRobust secretionCancer cellsCD8TA responsesPatientsImmunomodulatory characterCancerCulture model
2004
Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease
Maeda Y, Levy R, Reddy P, Liu C, Clouthier S, Teshima T, Ferrara J. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 2004, 105: 2023-2027. PMID: 15466930, DOI: 10.1182/blood-2004-08-3036.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsBone Marrow TransplantationCD8-Positive T-LymphocytesCell Culture TechniquesFas Ligand ProteinGraft vs Host DiseaseHistocompatibilityHistocompatibility Antigens Class ILymphocyte TransfusionMembrane GlycoproteinsMiceMice, Inbred StrainsModels, AnimalPerforinPore Forming Cytotoxic ProteinsTransplantation, HomologousConceptsT cellsHost diseaseAllogeneic bone marrow transplantationT cell-mediated cytotoxicityTumor necrosis factor alphaMajor histocompatibility complex class IGreater serum levelsDonor T cellsBone marrow transplantationCell-mediated cytotoxicityHistocompatibility complex class IWild-type T cellsNecrosis factor alphaComplex class ILethal GVHDAcute graftAlloreactive CD8Histopathologic damageMarrow transplantationSerum levelsAlloantigen stimulationIrradiated murine modelFactor alphaCD8Murine model
1995
Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand.
Höllsberg P, Weber WE, Dangond F, Batra V, Sette A, Hafler DA. Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. Proceedings Of The National Academy Of Sciences Of The United States Of America 1995, 92: 4036-4040. PMID: 7732026, PMCID: PMC42097, DOI: 10.1073/pnas.92.9.4036.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceBinding SitesB-LymphocytesCD8-Positive T-LymphocytesCell DivisionCell Line, TransformedCytotoxicity, ImmunologicGene Products, taxHerpesvirus 4, HumanHLA-A2 AntigenHuman T-lymphotropic virus 1HumansKineticsLymphocyte ActivationMolecular Sequence DataMutagenesis, Site-DirectedPoint MutationThymidineConceptsCD8 T cellsInterleukin-2 secretionT cell receptor contact residuesT cellsReceptor contact residuesCD8 T cell clonesCytotoxic CD8 T cellsMyelopathy/tropical spastic paraparesisT cell-mediated cytotoxicityHAM/TSPTropical spastic paraparesisT cell clonesAltered peptide ligandT cell-mediated cytolysisHuman T-cell leukemia virus type IT cell stimulationVirus type IAnalog peptidesHLA-A2Spastic paraparesisNeurologic diseaseSecondary stimulationSecondary responsePeptide antigensPrimary activation
1979
T Cell-Mediated Cytotoxicity for L 929 Fibroblasts Infected with Banzi Virus (Flavivirus)
Sheets P, Schwartz A, Jacoby R, Bhatt P. T Cell-Mediated Cytotoxicity for L 929 Fibroblasts Infected with Banzi Virus (Flavivirus). The Journal Of Infectious Diseases 1979, 140: 384-391. PMID: 315440, DOI: 10.1093/infdis/140.3.384.Peer-Reviewed Original ResearchConceptsCytotoxicity of spleen cellsT cell-mediated cytotoxicityBanzi virusCell-mediated cytotoxicityC3H/RV miceSpecific cytotoxicityKiller cellsC3H/He miceSpleen cellsLethal infectionDecreased to background levelsVirus infectionViral inoculationFlaviviral encephalitisL-929 fibroblastsMiceCytotoxicityInfectionBanziCytotoxic activityDaysFibroblastsVirusC3H/RVCells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply